80 likes | 175 Views
PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model. SANOFI AT A GLANCE. We are a global healthcare company engaged in the research, development, manufacturing and marketing of healthcare solutions. €33 bn * In sales in 2013. OUR GROUP. R&D
E N D
PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCHTowards a more inclusive model
SANOFI AT A GLANCE • We are a global healthcare company engaged in the research, development, manufacturing and marketing of healthcare solutions. €33 bn* In sales in 2013 OUR GROUP R&D A major biopharmacy player * €32,951 M • 45%of revenues generated by biologics • 80%of development projects are biologics present in more than 100 countries A comprehensive offer of pharmaceuticals, vaccines and innovative therapeutic solutions 112 Industrial sites in 41 countries more than 110 000 employees Information of December 31st 2013 CONFERENCE OF MONTREAL 2014
Sanofi R&D ACCELERATE INNOVATION FOR PATIENTS We act as one to discover and develop therapies that prevent, treat and cure disease. Our main areas of research include: 49 Multiple Sclerosis Diabetes Oncology Rare Diseases Cardio-MetabolicDiseases Immunology Vaccines Animal Health projects and vaccines in clinical development* 9 high potential projects in late stage development* *Information provided as of February 6th, 2014 CONFERENCE OF MONTREAL 2014
The classicINNOVATION model The newINNOVATION model • OUR responsibility • Belief that advances in basic sciences can be easily translated to human disease • A linear process from discovery to development to market with little interactions throughout the innovation cycle • Focus on novel (but not necessarily validated) targets in humans • A strategy of “Many Shots on Goal” Change The R&D Innovation model • Anon-linear process that takes into account provider, purchaser and user metrics including pipeline activity, clinical success, regulatory approval, patient access, satisfaction of unmet need and overall value to society • A greater understanding of human disease • Open innovation and partnership Raising the batting average! CONFERENCE OF MONTREAL 2014
OurPRESIDENT OF R&D PATIENTS ARE THE MISSING LINK CONFERENCE OF MONTREAL 2014
Increasing public awareness & improving clinical trial education • SO WHAT ARE WE DOING ABOUT IT? MAKING CLINICAL TRIALS PATIENT FRIENDLY What do patients know about clinical research? How do they get their facts? How do they know if a study exists? Do they ever hear the results? Bringing patients within the project team e.g. Diabetes Patient Advisors input into study designs, innovation & outreach strategies Innovating to ease patient experience e-informed consent e-technology (e.g. telemetry) Point of care technologies (e.g. Dried Blood Spots) CONFERENCE OF MONTREAL 2014
Opportunities exists from target to use • So what are we doing about it? Before and Beyond clinical trials Target identification Path to proof of concept Effective value Access Partner in Patient Health (PiPH) initiative EU-NA PiPH Council Collaborate | Innovate Challenge Newly created position of Chief Patient Officer CONFERENCE OF MONTREAL 2014
OUR “RAISON D’ETRE” ACCELERATE INNOVATION FOR PATIENTS CONFERENCE OF MONTREAL 2014